Formulary guidance and transparency from P&T to point of care

Perspectives on NASH Market

Posted by Matt Breese on Feb 20, 2018

Find me on:


Non-alcoholic Steatohepatitis (NASH), the severest form of non-alcoholic fatty liver disease (NAFLD), is expected to become the leading cause of liver transplantation by 2020 in the United States. This untapped market might become the next big market in the metabolic disorders segment.  
Currently, lifestyle modifications, such as diet and regular exercise, are the main initial therapeutic step. Bariatric surgery is considered the last option, which improves histology and causes massive weight loss. 
The first entrants of NASH market are facing challenges including: high drug prices, physicians’ reluctance to prescribe NASH drugs, patients’ unwillingness to undergo diagnosis, difficulties of diagnosis and staging NASH, potential competition and the need for combination therapy. 
Jayachandra Reddy and Rishit Thakkar at asked new NASH market entrants to consider the following questions:
  • "What should be the optimum price for the first drug to convince payers, and make it a blockbuster as well?
  • "How can physician acceptance be increased? 
  • "How can the diagnosis rate be increased to get more patients to treat? 
  • "Are collaborations necessary to develop combination products?"
In terms of market strategy, they noted: 

"Different market access solutions such as forecasting, pricing strategies, business development/licensing evaluation, and go-to market strategies would help the early entrants for easy access, and increase the potential of their NASH products. Competent partners who have the industry know-how and relevant expertise in this arena can help them strategize better and identigy potential avenues."

Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Industry Trends, Market Access, Branding & Marketing